CA2224256C - Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes - Google Patents

Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes Download PDF

Info

Publication number
CA2224256C
CA2224256C CA 2224256 CA2224256A CA2224256C CA 2224256 C CA2224256 C CA 2224256C CA 2224256 CA2224256 CA 2224256 CA 2224256 A CA2224256 A CA 2224256A CA 2224256 C CA2224256 C CA 2224256C
Authority
CA
Canada
Prior art keywords
compound
mitogenic
antibody
group
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2224256
Other languages
English (en)
Other versions
CA2224256A1 (fr
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA 2224256 priority Critical patent/CA2224256C/fr
Publication of CA2224256A1 publication Critical patent/CA2224256A1/fr
Application granted granted Critical
Publication of CA2224256C publication Critical patent/CA2224256C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2224256 1997-12-09 1997-12-09 Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes Expired - Fee Related CA2224256C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2224256 CA2224256C (fr) 1997-12-09 1997-12-09 Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2224256 CA2224256C (fr) 1997-12-09 1997-12-09 Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes

Publications (2)

Publication Number Publication Date
CA2224256A1 CA2224256A1 (fr) 1999-06-09
CA2224256C true CA2224256C (fr) 2013-04-30

Family

ID=29275368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2224256 Expired - Fee Related CA2224256C (fr) 1997-12-09 1997-12-09 Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes

Country Status (1)

Country Link
CA (1) CA2224256C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927520T2 (de) 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont Verwendung von il-12 antikörpern zur behandlung von psoriasis
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
EP2433650A3 (fr) 2006-06-06 2012-12-19 Tolerrx Inc. Administration d'anticorps anti-CD3 dans le traitement de maladies auto-immunes
US20160158352A1 (en) 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans

Also Published As

Publication number Publication date
CA2224256A1 (fr) 1999-06-09

Similar Documents

Publication Publication Date Title
US7041289B1 (en) Method for treating established spontaneous auto-immune diseases in mammals
Chatenoud et al. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
Chatenoud et al. CD3-specific antibodies: a portal to the treatment of autoimmunity
JP2638652B2 (ja) カケクチンと反応するモノクロナール抗体
EP0663836B1 (fr) Traitement d'affections auto-immunes et inflammatoires
DE69534528T2 (de) Mehrstufiger kaskade-erhöhungs-impfstoff
WO1992007574A1 (fr) Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
CN117982639A (zh) 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
CN104519900A (zh) 用于治疗糖尿病的ctla4融合蛋白
US20130078238A1 (en) Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
CA2108886A1 (fr) Molecules dirigees contre les recepteurs a interleukine pour le traitement de l'arthrite inflammatoire
JP2852705B2 (ja) 自己免疫疾患の治療
JP2002540771A (ja) 抗体構築物およびケモカイン構築物ならびに自己免疫疾患の治療におけるそれらの使用
CA2224256C (fr) Methode de traitement de maladies autoimmunes spontanees et etablies chez les mammiferes
AU1287197A (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
Bach Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases
Bach Immunotherapy of insulin-dependent diabetes mellitus
DE69734392T2 (de) Impfstoff gegen tumore der b-lymphozyten
EP0303687B1 (fr) Compositions pour ameliorer les therapies adcc
JPH0641423B2 (ja) 細胞毒性薬剤組成物及び細胞毒性薬剤キット
Iuchi et al. Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses
Bardos et al. Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice
WO1997031648A1 (fr) Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
MAUFF et al. A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients.
De Jonge et al. Bispecific antibody treatment of murine B cell lymphoma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161209